drugset / Trial / NCT03824795
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of this Phase IIa study is to assess the safety, tolerability, and efficacy of incremental doses of MGB-BP-3 in patients with Clostridium difficile-associated diarrhea (CDAD).
Timeline
- Start
- 2019-02-07
- Primary completion
- 2020-04-03
- Completion
- 2020-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MGB-BP-3 | Small molecule | 125 mg | Oral |
| Comparator | MGB-BP-3 | Small molecule | 250 mg | Oral |
| Comparator | MGB-BP-3 | Small molecule | 500 mg | Oral |